이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

자폐 스펙트럼 장애로 진단된 첫 아이를 둔 임산부를 위한 치료 교육 프로그램의 평가 (AUTMER)

2026년 11월 4일 업데이트: Assistance Publique - Hôpitaux de Paris

자폐 스펙트럼 장애(ASD) 진단을 받은 첫 아이를 둔 임산부를 위한 치료 교육 프로그램 평가

Autism Spectrum Disorder (ASD) is a heterogeneous set of severe developmental abnormalities of the nervous system characterized by deficits affecting social interactions and verbal and non-verbal communication, as well as the presence of restricted interests, repetitive behaviors, and atypical sensory manifestations . ASD affects approximately 1% of the general population (Elsabbagh et al., 2012). Studies of siblings of individuals with ASD show that ASD is present in 7-20% of the offspring in families where a child has had a diagnosis of ASD and this prevalence increases if there are two diagnosed children.

Several studies show the benefits of interventions targeting parents' interaction strategies in the early phases of development of infants at high risk for ASDs, in reducing the risk itself or its severity. Very early intervention, due to the presence of significant brain plasticity at these stages, may be particularly effective in changing these emerging trajectories, from a "preventive intervention" perspective that would aim to mitigate developmental risk and alter prodromal symptom trajectories, rather than eliminate a condition.

Our hypothesis is that the implementation of a specific therapeutic education program during a new pregnancy in the mother of a child with a diagnosis of ASD (MER Program) could improve the mother's well-being, increase parenting communication skills, and thereby improve interaction with the newborn at high risk for ASD. If the infant is affected, it may also reduce the symptoms of the disorder. Indirectly, it could also improve the well-being of the other parent involved in the interaction.

The M.E.R (Mères Ecoute Ressources) programme is a therapeutic education intervention aimed at mothers of children with ASD during a new pregnancy. This programme, which is being piloted in France and Europe, involves a number of dimensions, both educational and behavioural (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).

The programme comprises 8 one-to-one sessions lasting 1.5 hours every 15 days. The first and last of these are for assessment purposes, with the 6 intermediate sessions constituting the support. The structure of the programme and the sessions is based on what is recommended in therapeutic education. The sessions can take place on the hospital site or by teleconsultation (remote consultation used in the context of healthcare).

연구 개요

상태

모병

상세 설명

Randomized controlled trial with deferred start, French multicenter stepped-wedge type.

The start date of the intervention in each center will be done by randomization, defining 2 periods: a control period located before the start of the intervention, and an experimental period located after the start of the intervention.

This design allows the principal investigating team to train the centers associated in turn with the intervention, and to have a control group with structured follow-up but without intervention.

All subjects will be included before 26 ADT and assigned to the control or experimental group, depending on the time of inclusion and the randomization of the center to which they belong.

The follow-up will be conducted in 2 phases: 1. during pregnancy and 2. After the birth of the child.

Subjects included were pregnant women who already had a child with an ASD diagnosis, the second parent if present, and the newborn at risk for an ASD diagnosis.

The primary objective of this study is to evaluate the effect of an innovative therapeutic education program (the MER program) versus control in pregnant women with a first child followed for ASD on the quality of interaction strategies of the mother-infant dyad at 10 months postpartum.

The primary endpoint was the caregiver non-directiveness subscore of the Manchester Assessment of Caregiver-infant Interaction (MACI) scale at 10 months postpartum. This subscore is both the most sensitive to intervention and predictive of ASD diagnosis.

The first secondary objective is the evaluation of the effect of the MER versus control program on:

  • maternal pregnancy-related anxiety (PRAQ-R2 score) ;
  • Anxious and depressive symptomatology and quality of life (WhoQoL-Bref score) in the mother and the second parent during pregnancy (EPDS score) and up to 20 months of age of the newborn (HAM-Anxiety and HAM-Depression scores);
  • perceived stress related to pregnancy (ALES score)
  • mother-infant interaction at 10 and 20 months (MACI score and subscore);
  • autistic signs in at-risk infants at 20 months (ADOS Toddler score);

The second secondary objective was to study variables that could impact the effect of the intervention, including

  • adherence: compliance with sessions, satisfaction of participants (PEI-Parent score) ;
  • other variables that could modulate the effect of the intervention: sociodemographic variables (socioeconomic level, family configuration, number of children); clinical profile of the mother (intellectual efficiency (Raven's PM score), psychiatric comorbidities (DIGS, SRS score)); clinical profile of the child already diagnosed (ADI-R and ADOS score; developmental level); clinical profile of the infant at risk (gestational age, MSEL, IBQ-R and ECBQ scores).

The third secondary objective was to describe the barriers and levers to the implementation of the intervention.

Characteristics related to the implementation of the intervention (recruitment, uptake, fidelity, and implementation) will be collected, as well as the profile of mothers who did not participate in the project.

연구 유형

중재적

등록 (추정된)

165

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Paris, 프랑스, 75019
        • 모병
        • Hôpital Robert Debré
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Mothers of children with a diagnosis of ASD, in pregnancy (before the 26th week of amenorrhea);
  • The diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including if possible: the Autism Diagnostic Observation Schedule ADOS, and/or ADI
  • Informed consent from mother and sec

Exclusion Criteria:

  • Presence of a clearly identified and unstabilized severe psychiatric disorder in the mother (confirmed by medical interview and DIGS questionnaire conducted at the time of the inclusion visit) and/or intellectual disability;
  • Engagement in another form of individual therapeutic intervention.
  • Refusal of either parent (for child assessment, primary criterion)
  • Parents not proficient in French language
  • Persons (mother or second parent) under legal protection, guardianship or trusteeship, persons deprived of liberty, under court protection, under psychiatric care, under constraint, admitted to a health or social institution for purposes other than research
  • Persons with cognitive disorders or intellectual disabilities

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: control group

Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)

실험적: experimental group

Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)

The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).

It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or teleconsultation (remote consultation used in the context of healthcare).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Manchester Assessment of Caregiver-infant Interaction (MACI) "caregiver non-directiveness" subscore
기간: 5 months after delivery

mother-baby interaction in the experimental group versus the control group at 5 months postpartum.

This subscore is the most sensitive to intervention and predictive of ASD diagnosis.

5 months after delivery

2차 결과 측정

결과 측정
측정값 설명
기간
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
기간: between 11 weeks and 26 weeks of gestation

To evaluate the effect of the MER program on maternal anxiety related to pregnancy

between 11 weeks and 26 weeks of gestation
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
기간: at 3 months after intervention

To evaluate the effect of the MER program on maternal anxiety related to pregnancy

at 3 months after intervention
Appraisal of Life Events Scale (ALES)
기간: between 11 weeks and 26 weeks of gestation

Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale)

between 11 weeks and 26 weeks of gestation
Appraisal of Life Events Scale (ALES)
기간: at 3 months after intervention

Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale

at 3 months after intervention
Edimburgh Postnatal Depression Scale (EPDS)
기간: 10 months after birth

used to assess the risk of postnatal depression and is useful for identifying the presence of anxiety symptoms.The threshold retained for the French validation is 10.5, above which a depression is possible and below which the risk is very low.

10 months after birth
quality of life score-Bref (WhoQol-Bref)
기간: 10 months after birth

WHOQOL-BREF includes 26 items that measure the following broad domains: physical health, psychological health, social relationships and environment.

10 months after birth
parental anxiety score (HAM)
기간: 10 months after birth

hetero-questionnaire with 14 items, measuring both the psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) expression of anxiety. Each item is rated on a Likert scale from 0 to 4 (total range 0-56, where <17= mild anxiety; 18-24= mild to moderate; 25-30 moderate to severe)

10 months after birth
mother's intelligence quotient
기간: between 11 weeks and 26 weeks of gestation

measured by Raven's Progressive Matrices

between 11 weeks and 26 weeks of gestation
Social Responsiveness Scale (SRS)
기간: between 11 weeks and 26 weeks of gestation

to refine the evaluation of social difficulties in a dimensional way

between 11 weeks and 26 weeks of gestation
Wechsler Mullen scale
기간: between 11 weeks and 26 weeks of gestation

developmental level of the ASD child

between 11 weeks and 26 weeks of gestation

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Anita Beggiato, PHD, APHP

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 5월 13일

기본 완료 (추정된)

2029년 3월 13일

연구 완료 (추정된)

2029년 8월 13일

연구 등록 날짜

최초 제출

2021년 10월 11일

QC 기준을 충족하는 최초 제출

2021년 10월 22일

처음 게시됨 (실제)

2021년 11월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다